LYRA THERAPEUTICS INC (LYRA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:LYRA • US55234L2043

1.82 USD
+0.05 (+2.82%)
At close: Feb 6, 2026
1.91 USD
+0.09 (+4.95%)
After Hours: 2/6/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall LYRA gets a fundamental rating of 2 out of 10. We evaluated LYRA against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of LYRA have multiple concerns. LYRA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year LYRA has reported negative net income.
  • LYRA had a negative operating cash flow in the past year.
  • In the past 5 years LYRA always reported negative net income.
  • In the past 5 years LYRA always reported negative operating cash flow.
LYRA Yearly Net Income VS EBIT VS OCF VS FCFLYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • LYRA's Return On Assets of -75.38% is on the low side compared to the rest of the industry. LYRA is outperformed by 72.25% of its industry peers.
Industry RankSector Rank
ROA -75.38%
ROE N/A
ROIC N/A
ROA(3y)-78.35%
ROA(5y)-68.36%
ROE(3y)-314.8%
ROE(5y)-220.22%
ROIC(3y)N/A
ROIC(5y)N/A
LYRA Yearly ROA, ROE, ROICLYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LYRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYRA Yearly Profit, Operating, Gross MarginsLYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • LYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LYRA has more shares outstanding
  • LYRA has more shares outstanding than it did 5 years ago.
  • LYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LYRA Yearly Shares OutstandingLYRA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
LYRA Yearly Total Debt VS Total AssetsLYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • Based on the Altman-Z score of -15.69, we must say that LYRA is in the distress zone and has some risk of bankruptcy.
  • LYRA has a worse Altman-Z score (-15.69) than 79.58% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.69
ROIC/WACCN/A
WACC9.42%
LYRA Yearly LT Debt VS Equity VS FCFLYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

  • LYRA has a Current Ratio of 2.43. This indicates that LYRA is financially healthy and has no problem in meeting its short term obligations.
  • LYRA has a Current ratio (2.43) which is in line with its industry peers.
  • A Quick Ratio of 2.43 indicates that LYRA has no problem at all paying its short term obligations.
  • The Quick ratio of LYRA (2.43) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.43
LYRA Yearly Current Assets VS Current LiabilitesLYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • LYRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.28%, which is quite impressive.
  • Looking at the last year, LYRA shows a very negative growth in Revenue. The Revenue has decreased by -59.21% in the last year.
  • The Revenue has been growing by 74.24% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)69.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.44%
Revenue 1Y (TTM)-59.21%
Revenue growth 3Y74.24%
Revenue growth 5YN/A
Sales Q2Q%-87.18%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.65% on average over the next years. This is quite good.
  • LYRA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 111.38% yearly.
EPS Next Y63.39%
EPS Next 2Y37.84%
EPS Next 3Y24.06%
EPS Next 5Y14.65%
Revenue Next Year-51.56%
Revenue Next 2Y-32.22%
Revenue Next 3Y95.96%
Revenue Next 5Y111.38%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LYRA Yearly Revenue VS EstimatesLYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M
LYRA Yearly EPS VS EstimatesLYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600 -800 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LYRA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LYRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYRA Price Earnings VS Forward Price EarningsLYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYRA Per share dataLYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • LYRA's earnings are expected to grow with 24.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.84%
EPS Next 3Y24.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • LYRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LYRA THERAPEUTICS INC

NASDAQ:LYRA (2/6/2026, 8:00:00 PM)

After market: 1.91 +0.09 (+4.95%)

1.82

+0.05 (+2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-11
Inst Owners19.97%
Inst Owner Change-7.37%
Ins Owners0.01%
Ins Owner Change-0.1%
Market Cap3.22M
Revenue(TTM)600.00K
Net Income(TTM)-32.95M
Analysts48.89
Price Target16.32 (796.7%)
Short Float %2.18%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.6%
Min EPS beat(2)10.27%
Max EPS beat(2)36.94%
EPS beat(4)3
Avg EPS beat(4)7.6%
Min EPS beat(4)-30.72%
Max EPS beat(4)36.94%
EPS beat(8)5
Avg EPS beat(8)-8.45%
EPS beat(12)8
Avg EPS beat(12)-2.76%
EPS beat(16)10
Avg EPS beat(16)-1.48%
Revenue beat(2)1
Avg Revenue beat(2)-41.33%
Min Revenue beat(2)-87.43%
Max Revenue beat(2)4.77%
Revenue beat(4)2
Avg Revenue beat(4)-18.5%
Min Revenue beat(4)-87.43%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)-10.71%
Revenue beat(12)7
Avg Revenue beat(12)20.41%
Revenue beat(16)8
Avg Revenue beat(16)12.56%
PT rev (1m)-30.43%
PT rev (3m)-30.43%
EPS NQ rev (1m)-90.02%
EPS NQ rev (3m)-63.76%
EPS NY rev (1m)-39%
EPS NY rev (3m)-32.91%
Revenue NQ rev (1m)-4.43%
Revenue NQ rev (3m)-4.43%
Revenue NY rev (1m)26.26%
Revenue NY rev (3m)-2.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.37
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.89
EYN/A
EPS(NY)-7.16
Fwd EYN/A
FCF(TTM)-19.27
FCFYN/A
OCF(TTM)-19.29
OCFYN/A
SpS0.34
BVpS-2.45
TBVpS-2.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -75.38%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.35%
ROA(5y)-68.36%
ROE(3y)-314.8%
ROE(5y)-220.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.45%
Cap/Sales 6.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.43
Altman-Z -15.69
F-Score3
WACC9.42%
ROIC/WACCN/A
Cap/Depr(3y)295.99%
Cap/Depr(5y)601.39%
Cap/Sales(3y)77.13%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.44%
EPS Next Y63.39%
EPS Next 2Y37.84%
EPS Next 3Y24.06%
EPS Next 5Y14.65%
Revenue 1Y (TTM)-59.21%
Revenue growth 3Y74.24%
Revenue growth 5YN/A
Sales Q2Q%-87.18%
Revenue Next Year-51.56%
Revenue Next 2Y-32.22%
Revenue Next 3Y95.96%
Revenue Next 5Y111.38%
EBIT growth 1Y51.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.48%
OCF growth 3YN/A
OCF growth 5YN/A

LYRA THERAPEUTICS INC / LYRA FAQ

What is the fundamental rating for LYRA stock?

ChartMill assigns a fundamental rating of 2 / 10 to LYRA.


Can you provide the valuation status for LYRA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to LYRA THERAPEUTICS INC (LYRA). This can be considered as Overvalued.


How profitable is LYRA THERAPEUTICS INC (LYRA) stock?

LYRA THERAPEUTICS INC (LYRA) has a profitability rating of 0 / 10.


What is the financial health of LYRA THERAPEUTICS INC (LYRA) stock?

The financial health rating of LYRA THERAPEUTICS INC (LYRA) is 3 / 10.